Title (fr)

Publication

Application

Priority

US 0104813 W 20010215

US 18271000 P 20000215

US 21642200 P 20000706

US 24353200 P 20001027

Abstract (en)

[origin: WO0160814A2] The present invention relates to pyrrole substituted 2-indolinone compounds of formula (I): and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefor are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

[origin: WO0160814A2] The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

2014-05-28[REG GB SPCX] CORRECTION OF AN ERRATUM IN THE GAZETTE CONCERNING A SUPPLEMENTARY PROTECTION CERTIFICATE

- Free text: SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB10/008 GRANTED TO SUGEN INC. AND PHARMACIA AND UPJOHN COMPANY LLC IN RESPECT OF THE PRODUCT TOCERANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE PHOSPHATE SALT.?, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6380 DATED 31 AUGUST 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 24 SEPTEMBER 2024